TCM
AMLX icon

Tybourne Capital Management’s Amylyx Pharmaceuticals AMLX Stock Holding History

Tybourne Capital Management’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-768,603
Closed -$14.8M – 27
2022
Q2 		$14.8M Hold
768,603
– – 1.07% 24
2022
Q1 		$9.88M Buy
+768,603
New +$17.4M 0.58% 26

Other funds holding AMLX

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Tybourne Capital Management's AMLX Position: Q3 2022 in Review

Tybourne Capital Management sold out of Amylyx Pharmaceuticals (AMLX) in Q3 2022, closing a stake of 768,603 shares — an estimated $14.8M sold.

Tybourne Capital Management first reported a position in AMLX in Q1 2022 and held it in 2 quarters. The position peaked at $14.8M in Q2 2022. 95 funds tracked by Wall St. Rank hold AMLX as of Q3 2022.

  • Tybourne Capital Management reported no remaining Amylyx Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • Tybourne Capital Management sold 768,603 Amylyx Pharmaceuticals shares in Q3 2022, an estimated $14.8M.
  • Tybourne Capital Management first reported a position in Amylyx Pharmaceuticals in Q1 2022 and held it in 2 quarters.
  • Tybourne Capital Management's Amylyx Pharmaceuticals position peaked at $14.8M in Q2 2022.
  • 95 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q3 2022.

Based on Tybourne Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.